Octreotide for the treatment of diarrhoea in patients with ileal pouch anal anastomosis: A placebo-controlled crossover study

Colorectal Disease

Volumn 14, Issue 4, 2012, Pages

  Van Assche, G ^a   Ferrante, M ^a   Vermeire, S ^a   Noman, M ^a   Rans, K ^a   Van der Biest, L ^a   Penninckx, F ^a   Wolthuis, A ^a   Rutgeerts, P ^a   D'Hoore, A ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Diarrhoea; Ileal pouch anal anastomosis; Medical therapy; Octreotide; Somatostatin; Ulcerative colitis

Indexed keywords

ANTIDIARRHEAL AGENT; OCTREOTIDE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANUS DISEASE; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEFECATION URGENCY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLEXIBLE POUCHOSCOPY; HOARSENESS; HUMAN; HUMAN TISSUE; ILEAL POUCH ANAL ANASTOMOSIS; ILEITIS; ILEOANAL ANASTOMOSIS; INFLUENZA; INJECTION SITE REACTION; INTESTINE BIOPSY; INTESTINE ENDOSCOPY; MALE; NAUSEA; OUTCOME ASSESSMENT; PAIN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; COLITIS, ULCERATIVE; COLONIC POUCHES; CROSS-OVER STUDIES; DIARRHEA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OCTREOTIDE; POSTOPERATIVE COMPLICATIONS; POUCHITIS; PROCTOCOLECTOMY, RESTORATIVE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84857951688     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2011.02838.x     Document Type: Article

References (20)

1. Biancone L, Michetti P, Travis S et al. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008; 2: 63-92.
2. Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990; 211: 622-7.
3. Ferrante M, Declerck S, De Hertogh G et al. Outcome after proctocolectomy with ilealpouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis 2008; 14: 20-8.
4. Shen B, Achkar JP, Lashner BA et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 2002; 97: 972-7.
5. Fazio VW, Ziv Y, Church JM et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222: 120-7.
6. Lovegrove RE, Heriot AG, Constantinides V et al. Meta-analysis of short-term and long-term outcomes of J, W and S ileal reservoirs for restorative proctocolectomy. Colorectal Dis 2007; 9: 310-20.
7. Gebbia V, Carreca I, Testa A et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993; 4: 443-5.
8. Goumas P, Naxakis S, Christopoulou A, Chrysanthopoulos C, Nikolopoulou VV, Kalofonos HP. Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist 1998; 3: 50-3.
9. Ladefoged K, Christensen KC, Hegnhøj J, Jarnum S. Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome. Gut 1989; 30: 943-9.
10. Ippoliti C, Champlin R, Bugazia N et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3350-4.
11. Shen B, Achkar J-P, Connor JT et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum 2003; 46: 748-53.
12. Nicholls J, Wynick D, Domin J, Sandler LM, Bloom SR. Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly. Clin Endocrinol (Oxf) 1990; 32: 545-50.
13. Fried M. Octreotide in the treatment of refractory diarrhea. Digestion 1999; 60(Suppl. 2): 42-6.
14. Zachariah B, Gwede CK, James J et al. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst 2010; 102: 547-56.
15. Martenson JA, Halyard MY, Sloan JA et al. Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA. J Clin Oncol 2008; 26: 5248-53.
16. Simon DM, Cello JP, Valenzuela J et al. Multicenter trial of octreotide inpatients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995; 108: 1753-60.
17. Gullichsen R. Long-acting octreotide in the treatment of diarrhea after pelvic pouch surgery. Tech Coloproctol 2006; 10: 346-9.
18. Hasler WL, Soudah HC, Owyang C. Mechanisms by which octreotide amelioratessymptoms in the dumping syndrome. J Pharmacol Exp Ther 1996; 277: 1359-65.
19. Sagar PM, Finigan P, Taylor BA. Lack of response of pouch dysfunction to the somatostatin analogue octreotide. Br J Surg 1994; 81: 1064.
20. van Keimpema L, Nevens F, Vanslembrouck R et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-8.